Kostas Stamatopoulos, MD, PhD, of the Center for Research and Technology Hellas, Thermi, Greece, explores the result of an ERIC multi-center study evaluating the use of next-generation sequencing to identify micro-clones with TP53 mutations in chronic lymphocytic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).